At San Diego-based CDMO and CRO Abzena, Geoffrey M Glass has stepped into the CEO role. Glass has served as Chairman of the ...

MSD, known as Merck & Co in the US and Canada, licensed rights to Lenvima in 2018 in a near-$6 billion deal aimed at ...

BBP-418 hit the mark in the phase 3 FORTIFY trial by achieving a significant increase in glycosylated alpha-dystroglycan (αDG), which is impaired in LGMD and causes muscle wasting, initially in the ...

The news on vaccines was not so good, as declining sales of shingles shot Shingrix in the US and China pegged back growth to ...

At ESMO this year, AstraZeneca presented final overall survival results from the MATTERHORN Phase III Trial for patients with ...

CSL's already depressed share price sank further on the news of the delay, which chairman Dr Brian McNamee said was related ...

Eli Lilly and tech giant NVIDIA have joined forces on an ambitious plan – building the most powerful AI-powered supercomputer ...

The FDA has responded to the increasing use of artificial intelligence (AI) in the discovery and development of drugs and biologics by publishing its first provisional guidance on the technology's use ...

In an ambitious move, Moderna has teamed up with OpenAI, the artificial intelligence company behind ChatGPT, to further integrate generative AI (GenAI) across its mRNA drug development and ...

President Donald Trump's plan to introduce a most favoured nation (MFN) system of drug pricing controls is not quite what he first said it would be, according to a statement from the administration.

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday. A total of 106 patients with short ...

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab as a ...